Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.48 - $8.02
Previous CloseN/A
Volume530.95K
Average Volume (3M)2.84M
Market Cap
$1.26B
Enterprise Value$942.61M
Total Cash (Recent Filing)$59.28M
Total Debt (Recent Filing)$257.22M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding161,480,360
10 Day Avg. Volume2,179,450
30 Day Avg. Volume2,841,219
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.83
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda127.50
Forecast
1Y Price Target
$7.70Price Target Upside-1.66% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsSignificant clinical validation following Corcept's positive CATALYST trial readout.
Product PenetrationStronger-than-expected Recorlev volume growth driven by increased penetration into the difficult-to-control type-2 diabetes market.
Revenue GrowthXeris delivered strong revenues representing a robust growth, demonstrating management's increased confidence in their outlook and presenting a favorable setup for investors.
Bears Say
Competition ImpactKeveyis faced a modest revenue decrease due to generic competition, though the addition of new patients helped slow the decline.
Execution RisksAcknowledgement of execution risks given the nascent recognition of this patient population.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $2.48 and its highest was $8.02 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.26B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 66 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.018.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Overvalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 161,480,360 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 20.219%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.70 (-1.66% Downside)
$7.70 (-1.66% Downside)
Blogger Sentiment
Bullish
XERS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 671.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.64%
12-Months-Change
Fundamentals
Return on Equity
222.83%
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and growth, particularly in revenue and product demand. Key products like Recorlev showed exceptional growth, and the company successfully raised its revenue guidance. However, there were challenges with increased expenses affecting gross margin and SG&A costs.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$7.70
▼(-1.66% Downside)
Technical Analysis
Xencor
―
Zymeworks
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
Ownership Overview
5.75% Insiders
9.23% Mutual Funds
10.94% Other Institutional Investors
62.13% Public Companies and Individual Investors